Anil Raghavan - Chief Executive Officer
Mr. Anil Raghavan is the Chief Executive Officer of SPARC since April, 2014. In his role as CEO, Mr Raghavan sets SPARC’s strategic priorities and focuses on developing the portfolio prudently and driving long-term stockholder value.
Mr. Raghavan is a senior Pharmaceutical Services executive with significant global exposure spanning business strategy and operations. Prior to joining SPARC in 2014, he served as the Managing Director of India and Sri Lanka business of Quintiles and has been an active member of their Asia Management Board. Under his watch, Quintiles India maintained strong double-digit revenue and operating surplus growth in a turbulent business environment. He spent the first half of his career in the Consulting Industry with leading firms such as Arthur Andersen, KPMG and Cambridge Technology Partners. He helped the leadership teams of several companies in developing/evaluating strategies and improving business performance. He has led/participated in several industry sector studies, working with business lobbies and industry associations to highlight sectoral opportunities and challenges. Mr. Raghavan is an Industrial Engineer with a deep interest in evolving science and technologies enabling pharmaceutical R&D and health care. His other interests include the New Media, Digital Photography and Carnatic Music.
Nitin Dharmadhikari - Executive Vice-President Formulation Development
Dr. Nitin Dharmadhikari Executive Vice-President – R&D (Formulation Development) oversees the development of innovative formulation's based on SPARC’s proprietary Novel Drug Delivery Platforms.
Dr. Dharmadhikari has more than 25 years of Industry experience. After working with companies like Dr. Reddy’s & Ranbaxy, he joined Sun Pharma in 1999 and looked after generic product development for US and Europe.He moved to SPARC in March 2007. He is a co-inventor of two innovative platform technologies i.e., Wrap Matrix™ and GRID™ technologies. He is inventor or co-inventor of more than 50 patent / patent applications.
Siu-Long Yao - Sr. Vice–President Clinical Development & Operations
Siu-Long Yao, Sr. Vice-President for Clinical Development & Operations, oversees design & execution of clinical research globally.
Siu brings in 20 years of experience in clinical research. Prior to joining SPARC, he held positions of increasing responsibility in Clinical Pharmacology & Oncology at Merck, Sanofi-Aventis and Schering-Plough. He completed sub-specialty training in hematology & oncology at Johns Hopkins and is a Board certified Internist, Hematologist and Oncologist.
Nitin Damle - Sr. Vice-President and Chief Innovation Officer
Nitin Damle, Sr. Vice–President and Chief Innovation Officer, oversees collaboration with external partners and leads the development of Biologics at SPARC.
Nitin brings in 30 years of experience in drug discovery and preclinical development in Oncology and Immuno-Inflammatory therapeutic areas with focus on both small molecules and biologics. He was Director of Oncology and Immuno-Inflammatory diseases at Wyeth, and Sr. Director of Preclinical Research at Endo Pharmaceuticals before joining SPARC.
Trinadha Rao Chitturi - Sr. Vice–President Medicinal Chemistry
Dr. Trinadha Rao Chitturi, Sr. Vice–President & Head, Medicinal Chemistry, oversees design and synthesis of NCE’s for therapeutic targets of interest with regard to the new drug discovery programs.
Dr Rao carries over 22 years of experience in synthetic organic/ medicinal chemistry together at SPIL & SPARC Ltd. Prior to joining SUN, Dr Rao was associated with GlaxoSmithkline Pharmaceuticals Ltd. Thane, as Group Leader in Chemistry R&D. for about 4 years.
Vikram Ramanathan - Vice-President and Head of Translational Development
Vikram Ramanathan, Vice-President and Head of Translational Development at SPARC, is responsible for Preclinical Pharmacology, Drug Metabolism & Pharmacokinetics and Bioanalysis, and Regulatory Toxicology. Vikram has 20+ years’ experience in Pharma Drug Discovery and Development having worked both in the US and in India.
Vikram received his PhD in Pharmaceutical Chemistry (Pharmaceutics Pathway) at the University of California San Francisco where he studied the role of mammalian epithelial neurotransmitter transporters in pharmacokinetics and disposition in the laboratory of Dr Kathleen M. Giacomini. He then did a post-doctoral fellowship in molecular neurobiology at the NIH, Bethesda in the laboratory of Dr Zach W. Hall, studying the oligomerization of the muscarinic acetylcholine receptor.
Vikram started his pharma career at SmithKline Beecham Pharmaceuticals in the Philadelphia area spending several years in its DMPK department before returning to India in 2003. He joined Advinus Therapeutics Ltd. with its founding team to set up its DMPK and Bioanalysis department in Bangalore and was also responsible for clinical candidate optimization. He then worked at Cadila Healthcare Ltd. as Vice President and Head, supporting DMPK and Bioanalysis for NCEs, generics and biologicals. In his most recent stint Vikram was Sr. Vice President & COO of Advinus Therapeutics with responsibility for the scientific functions including Chemistry, Analytical R&D, Pharmacology, DMPK & Bioanalysis and Safety Assessment.
Chetan Rajpara - Chief Financial Officer
Chetan Rajpara, CFO, joined SPARC in February 2017 and is responsible for Finance, Accounts, Taxation and Legal & Secretarial functions.
Prior to joining SPARC, Chetan was associated with Sun Pharma since 1993 and has spent over 24 years with Sun Pharma in various leadership positions and has worked across multiple areas like Accounts, Distribution, International Logistics and Finance & Treasury.
Chetan was instrumental in setting up Treasury for Sun Pharma in 2003. He was designated Vice-President in April 2016 and was responsible for FX & Interest Rate Risk Management, Cash & Liquidity Management, Fund Raising, Investments, Banking Relationships, International Trade Transactions, RBI Compliance and Global Insurance Programme.
Chetan worked with The Dharamsi Morarji Chemical Company Limited as Chief Accountant from 1990 to 1993. He is a Graduate Member of ICWAI, Calcutta (1989) and a Commerce Graduate with distinction from H.L. College of Commerce, Ahmedabad (1986). Chetan completed his Post Graduate Executive Management Programme from SP Jain Institute of Management & Research, Mumbai in 2014.
Shravanti Bhowmik - Vice–President Program Management
Dr. Shravanti Bhowmik, Vice–President & Head, Program Management, oversees all aspects of the development/implementation of projects and programs involving cross-functional teams, coordinating between line management, internal, and external resources, planning and directing schedules as well as project budgets.
Shravanti carries over 17 years of experience in academics, medical affairs, medico-marketing, pharmacovigilance, clinical operations, and clinical development. She is a clinical pharmacologist, post graduate in executive management from S.P. Jain Institute of Management & Research, Mumbai, and a Project Management Professional, Certified through Project Management Institute.
Michael Choi - Vice-President Business Development
Michael Choi, Vice-President and Head of Business Development at SPARC, is responsible for global business development, commercial strategy and investor relations.
Michael holds an MBA in Finance and Economics from Columbia Business School and a BA in History with a Pre-Medical Sciences concentration from Columbia College in New York. Michael has over 20 years of experience in strategy, business development and investments in the biopharmaceutical industry and has successfully completed corporate transactions in six continents. His areas of expertise include search and evaluation of biopharmaceutical assets, product and pipeline valuations, and structuring partnership deals in an international setting.
Prior to joining SPARC, Michael was the Business Alliance Lead for Greater China, Asia-Pacific, Latin America and Canada for Pfizer Essential Health. He also held roles at Life Technologies (now Thermo Fisher Scientific), FrankelGroup (now Huron Consulting), Envision Consulting Group (now IQVIA) and PricewaterhouseCoopers. Michael started his career in clinical research at the Columbia Presbyterian Medical Center Department of Cardiothoracic and Vascular Surgery
Shanta Gupta - Chief Human Resource Officer
Shanta Gupta, Chief Human Resource Officer is responsible for the organization’s human capital management, steering the company towards progress by aligning human potential with the organization’s vision, mission and goals.
Prior to joining SPARC, Shanta was CHRO for the EPC business of Reliance Infrastructure, instrumental in successfully transforming its business model through change management. She played a crucial role in the start up, successful production and divestment of its Cement business. Before joining Reliance she held roles in many HR consulting companies, one of them being Stantonchase International, whereas Associate Director she has recruited several top leaders in the Financial Services industry.
Shanta has over 25 years of experience across industry verticals like Manufacturing, Financial Services, and Infrastructure. She has expertise in conceptualizing and aligning Human Resources in line with the overall business strategy. She has wide experience in assessing existing processes and accordingly designing and implementing measures aimed at enhancing process efficiency, organizational effectiveness and employee potential.
Shanta has done her Post Graduation from Jadavpur University and has been identified as the 100 Top HR Minds by World HRD Congress.
Rajesh Ranganathan - Vice-President Partnerships and Portfolio Strategy
As a member of the SPARC management team, Dr Ranganathan oversees all aspects of academic collaborations from cultivation of relationship, opportunity triage, due diligence; manages operational/business aspects of all ongoing collaborations. In addition, he is responsible for revamping the internal ideation process, and facilitating decision making on project progression and resource allocation for our pre-clinical portfolio, based on priority, risk, and competition.
Dr Ranganathan received his Ph.D. in Biology from Massachusetts Institute of Technology and did his post-doctoral training in neuroscience at Harvard Medical School & Fred Hutchison Cancer Research Centre. He has around 20 years of experience in various domains of translational research and drug discovery. Most recently, Dr Ranganathan was the Director of Translational Medicine Initiatives and Clinical Partnerships at Massachusetts General Hospital (MGH), Boston for 3+ years, where he established a flagship internal medicine residency training program that focuses on elucidating the causes of serious and perplexing ailments that defy a definitive diagnosis or are refractory to existing treatments; and conducted business development with biotech and pharma to bring clinical studies to be conducted at the Translational Research Centre at MGH. In parallel, he served as a part-time consultant for SPARC, where he has spearheaded scientific listening visits for the SPARC executive team to 20+ US academic institutions and has been instrumental in establishing multi-year drug discovery collaborations with four academic institutions, with the flagship program to date being a $10M research collaboration deal with University of Michigan. Additionally, he serves as an adjunct professor at Drexel University.
Previously, he served for one year as the VP of Science and Regulatory Advocacy at PhRMA (Pharmaceutical Researchers and Manufacturers of America) in Washington DC. Prior to his time at PhRMA, for 3+ years, Dr Ranganathan was the Director of the Office of Translational Research at the National Institutes for Neurological Disorders and Stroke (NINDS) at the NIH. He transitioned to this role at NINDS after serving as the Senior Advisor to the NIH Director for Translational Medicine for 15 months. He joined the NIH in 2010 after spending 7+ years at the Novartis Institutes for Biomedical Research Inc., where he was a Director in the scientific strategy & portfolio management group and also founded & served as the Global Head of the Office of Scientific Education for the Institutes.